Side-by-side · Research reference

CardiogenvsProstamax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BAnimal-MechanisticHUMAN-REVIEWED11/38 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

01Mechanism of Action

Parameter

Cardiogen

Prostamax

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Chromatin in prostatic cells — pericentromeric heterochromatin regions

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

—

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

Prostamax

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

—

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

—

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Route

Subcutaneous injection

—

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

Effective concentration (in vitro)

—

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

Human clinical dose

—

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

Age groups studied

—

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

04Side Effects & Safety

Parameter

Cardiogen

Prostamax

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

Published adverse events

—

None reported in available literature

Genotoxicity signals

—

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

Metal ion interactions

—

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

Human safety data

—

Absent — no published Phase 1/2/3 trials

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

05Administration Protocol

Parameter

Cardiogen

Prostamax

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

3. Timing

Variable — often evening injection. No established circadian preference.

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

Prostamax

— no documented stacks